The contribution of MRI in assessing cognitive impairment in multiple sclerosiss

Neurology

Volumn 75, Issue 23, 2010, Pages 2121-2128

  Filippi, M ^a   Rocca, M A ^a   Benedict, R H B ^b   Deluca, J ^c   Geurts, J J G ^d   Rombouts, S A R B ^e,f   Ron, M ^g   Comi, G ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

^c KESSLER FOUNDATION   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HLA DR ANTIGEN; INTERFERON BETA SERINE; RIVASTIGMINE;

ALZHEIMER DISEASE; BRAIN CORTEX; BRAIN DAMAGE; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; COGNITIVE REHABILITATION; DIFFUSION TENSOR IMAGING; FRACTIONAL ANISOTROPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HUMAN; MULTIPLE SCLEROSIS; NEUROANATOMY; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; REVIEW; WHITE MATTER;

ATROPHY; BRAIN; COGNITION DISORDERS; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS;

EID: 78650806336     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318200d768     Document Type: Review

References (60)

1. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008;7:1139-1151.
2. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: I: frequency, patterns, and prediction. Neurology 1991;41:685-691.
3. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008;7:615-625.
4. Benedict RHB, Cookfair D, Gavett R, et al. Validity of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS). J Int Neuropsychol Soc 2006;12: 549-558.
5. DeLuca J, Johnson SK, Natelson BH. Information processing efficiency in chronic fatigue syndrome and multiple sclerosis. Arch Neurol 1993;50:301-304.
6. DeLuca J, Gaudino EA, Diamond BJ, Christodoulou C, Engel RA. Acquisition and storage deficits in multiple sclerosis. J Clin Exp Neuropsychol 1998;20:376-390.
7. Rao SM. A Manual for the Brief, Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. National Multiple Sclerosis Society; 1991.
8. Benedict RHB, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 2002;16:381-397.
9. Drake A, Weinstock-Guttman B, Morrow S, Hojnacki D, Munschauer F, Benedict RHB. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 2010;16:228-237.
10. Parmenter BA, Weinstock-Guttman B, Garg N, Mun-schauer F, Benedict RHB. Screening for cognitive impairment in MS using the Symbol Digit Modalities Test. Mult Scler 2007;13:52-57.
11. Rovaris M, Comi G, Filippi M. MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. J Neurol Sci 2006;245:111-116.
12. Houtchens MK, Benedict RHB, Killiany R, et al. Tha-lamic atrophy and cognition in multiple sclerosis. Neurology 2007;69:113-123.
13. Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neu-rol Neurosurg Psychiatry 2001;70:773-780. (Pubitemid 32554208)
14. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-2712.
15. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64:247-254.
16. Amato MP, Portaccio E, Goretti B, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 2007; 64:1157-1161.
17. Morgen K, Sammer G, Courtney SM, et al. Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. Neuroimage 2006; 30:891-898.
18. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255-265.
19. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neu-rol 2001;50:389-400.
20. Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005;236:254-260.
21. Roosendaal SD, Moraal B, Pouwels PJ, et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler 2009;15:708-714.
22. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66:1144-1150.
23. Calabrese M, Rinaldi F, Mattisi I, et al. Widespread cortical thinning characterizes patients with MS with mild cognitive impairment. Neurology 2010;74:321-328.
24. Sicotte NL, Kern KC, Giesser BS, et al. Regional hip-pocampal atrophy in multiple sclerosis. Brain 2008;131: 1134-1141.
25. Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68:157-161.
26. Amato MP, Portaccio E, Stromillo ML, et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology 2008;71:632-638.
27. Khaleeli Z, Cercignani M, Audoin B, Ciccarelli O, Miller DH, Thompson AJ. Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. Neuroimage 2007;37:253-261. (Pubitemid 47068988)
28. Summers M, Fisniku L, Anderson V, Miller D, Cipolotti L, Ron M. Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier. Mult Scler 2008;14:197-204.
29. Rovaris M, Riccitelli G, Judica E, et al. Cognitive impairment and structural brain damage in benign multiple sclerosis. Neurology 2008;71:1521-1526.
30. Mesaros S, Rocca MA, Riccitelli G, et al. Corpus callosum damage and cognitive dysfunction in benign MS. Hum Brain Mapp 2009;30:2656-2666.
31. Roosendaal SD, Geurts JJ, Vrenken H, et al. Regional DTI differences in multiple sclerosis patients. Neuroimage 2009;44:1397-1403.
32. Dineen RA, Vilisaar J, Hlinka J, et al. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 2009;132:239-249.
33. Fink F, Eling P, Rischkau E, et al. The association between California Verbal Learning Test performance and fibre impairment in multiple sclerosis: evidence from diffusion tensor imaging. Mult Scler 2010;16:332-341.
34. Staffen W, Zauner H, Mair A, et al. Magnetic resonance spectroscopy of memory and frontal brain region in early multiple sclerosis. J Neuropsychiatry Clin Neurosci 2005; 17:357-363.
35. Gadea M, Martinez-Bisbal MC, Marti-Bonmati L, et al. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain 2004;127: 89-98.
36. Okuda DT, Srinivasan R, Oksenberg JR, et al. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by H MR spectroscopy and MRI measures. Brain 2009;132:250-259.
37. Portaccio E, Goretti B, Zipoli V, et al. APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. Mult Scler 2009;15:1489-1494.
38. van der Walt A, Stankovich J, Bahlo M, et al. Apolipopro-tein genotype does not influence MS severity, cognition, or brain atrophy. Neurology 2009;73:1018-1025.
39. Summers M, Swanton J, Fernando K, et al. Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry 2008; 79:955-958.
40. Audoin B, Au Duong MV, Ranjeva JP, et al. Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis. Hum Brain Mapp 2005;24: 216-228.
41. Mainero C, Caramia F, Pozzilli C, et al. fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. Neuroimage 2004;21:858-867.
42. Rocca MA, Valsasina P, Ceccarelli A, et al. Structural and functional MRI correlates of Stroop control in benign MS. Hum Brain Mapp 2009;30:276-290.
43. Waxman SG, Craner MJ, Black JA. Na+ channel expression along axons in multiple sclerosis and its models. Trends Pharmacol Sci 2004;25:584-591.
44. Tecchio F, Zito G, Zappasodi F, et al. Intra-cortical connectivity in multiple sclerosis: a neurophysiological approach. Brain 2008;131:1783-1792.
45. Penner IK, Rausch M, Kappos L, Opwis K, Radu EW. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. J Neurol 2003;250:461-472.
46. Rocca MA, Valsasina P, Absinta M, et al. Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology 2010;74:1252-1259.
47. Sperling RA, Dickerson BC, Pihlajamaki M, et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 2010;12:27-43.
48. Bobholz JA, Rao SM, Lobeck L, et al. fMRI study of episodic memory in relapsing-remitting MS: correlation with T2 lesion volume. Neurology 2006;67:1640-1645.
49. Audoin B, Reuter F, Duong MV, et al. Efficiency of cognitive control recruitment in the very early stage of multiple sclerosis: a one-year fMRI follow-up study. Mult Scler 2008;14:786-792.
50. Bonzano L, Pardini M, Mancardi GL, Pizzorno M, Roc-catagliata L. Structural connectivity influences brain activation during PVSAT in Multiple Sclerosis. Neuroimage 2009;44:9-15.
51. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002;162:2161-2169.
52. Patti F. Cognitive impairment in multiple sclerosis. Mult Scler 2009;15:2-8.
53. Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996;47:1463-1468.
54. Lanzillo R, Prinster A, Scarano V, et al. Neuropsychologi-cal assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b. J Neurol Sci 2006;245:141-145.
55. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-997.
56. Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci 2008;35:476-481.
57. Krupp LB, Christodoulou C, Melville P, Scherl WF, Ma-cAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004;63:1579-1585.
58. Parry AM, Scott RB, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 2003;126: 2750-2760.
59. Cader S, Palace J, Matthews PM. Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis. J Psycho-pharmacol 2009;23:686-696.
60. O'Brien AR, Chiaravalloti N, Goverover Y, Deluca J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 2008;89:761-769.